About Shire Viropharma (NASDAQ:VPHM)
ViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Shire Viropharma (NASDAQ:VPHM) Frequently Asked Questions
What is Shire Viropharma's stock symbol?
Shire Viropharma trades on the NASDAQ under the ticker symbol "VPHM."
How were Shire Viropharma's earnings last quarter?
Shire Viropharma Inc (NASDAQ:VPHM) issued its earnings results on Thursday, October, 24th. The biotechnology company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.05 by $0.15. The biotechnology company earned $113 million during the quarter, compared to analysts' expectations of $113.35 million. Shire Viropharma's quarterly revenue was up 24.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.10 EPS. View Shire Viropharma's Earnings History.
Who are some of Shire Viropharma's key competitors?
Some companies that are related to Shire Viropharma include Covance (CVD), Anacor Pharmaceuticals (ANAC), WuXi PharmaTech (Cayman) (WX), Genus (GNS), Albany Molecular Research (AMRI), Prosensa (RNA), Puretech Health (PRTC), Protalix Biotherapeutics (PLX), Cellular Dynamics International (ICEL), Horizon Discovery Group (HZD), Palatin Technologies (PTN), Silence Therapeutics (SLN), Bioventix (BVXP), Asterias Biotherapeutics (AST), Tissue Regenix Group (TRX), Matinas BioPharma (MTNB), Navidea Biopharmaceuticals (NAVB) and NovaBay Pharmaceuticals (NBY).
Has Shire Viropharma been receiving favorable news coverage?
News coverage about VPHM stock has been trending positive recently, Accern Sentiment reports. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Shire Viropharma earned a coverage optimism score of 0.39 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Shire Viropharma?
Shares of VPHM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How big of a company is Shire Viropharma?
Shire Viropharma has a market capitalization of $3.30 billion.
How can I contact Shire Viropharma?
Shire Viropharma's mailing address is 730 Stockton Dr, EXTON, PA 19341-1171, United States. The biotechnology company can be reached via phone at +1-610-4587300.
MarketBeat Community Rating for Shire Viropharma (VPHM)MarketBeat's community ratings are surveys of what our community members think about Shire Viropharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shire Viropharma (NASDAQ:VPHM) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Shire Viropharma (NASDAQ:VPHM) Earnings History and Estimates Chart
Shire Viropharma (NASDAQ VPHM) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/24/2013||Q313||$0.05||$0.20||$113.35 million||$113.00 million||View||N/A|
|8/1/2013||Q2 2013||$0.01||$0.15||$105.06 million||$104.00 million||View||N/A|
|5/1/2013||Q1 2013||$0.04||$0.15||$108.47 million||$107.00 million||View||N/A|
|2/27/2013||Q4 2012||$0.03||$0.10||$103.06 million||$106.50 million||View||N/A|
Shire Viropharma (NASDAQ:VPHM) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Shire Viropharma (NASDAQ:VPHM)
No dividend announcements for this company have been tracked by MarketBeat.com
Shire Viropharma (NASDAQ VPHM) News Headlines
Shire Viropharma (NASDAQ:VPHM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Shire Viropharma (NASDAQ:VPHM) Income Statement, Balance Sheet and Cash Flow Statement
Shire Viropharma (NASDAQ VPHM) Stock Chart for Wednesday, March, 21, 2018